Edition:
India

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

1.88USD
1:30am IST
Change (% chg)

$-0.12 (-6.00%)
Prev Close
$2.00
Open
$2.01
Day's High
$2.02
Day's Low
$1.86
Volume
34,146
Avg. Vol
108,436
52-wk High
$4.09
52-wk Low
$1.11

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $100.36
Shares Outstanding(Mil.): 52.27
Dividend: --
Yield (%): --

Financials

BRIEF-Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

02 Mar 2018

BRIEF-Sierra Oncology Announces Proposed Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

02 Mar 2018

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

27 Feb 2018

BRIEF-Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share

* SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​

27 Feb 2018

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly ‍net loss per share, basic and diluted $0.19​ Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Sierra Oncology appoints Dr. Andrew Allen to board

* Sierra Oncology appoints Dr. Andrew Allen to its board of directors Source text for Eikon: Further company coverage:

25 Oct 2017

Earnings vs. Estimates